enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Bamlanivimab - Wikipedia

    en.wikipedia.org/wiki/Bamlanivimab

    Bamlanivimab is a monoclonal antibody developed by AbCellera Biologics and Eli Lilly as a treatment for COVID-19. [8] The medication was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in November 2020, [9] [10] [11] and the EUA was revoked in April 2021. [12]

  3. Bamlanivimab/etesevimab - Wikipedia

    en.wikipedia.org/wiki/Bamlanivimab/etesevimab

    On 16 April 2021, the FDA revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. [13] The EUA was issued to Eli Lilly and Co. [3]

  4. Pemivibart - Wikipedia

    en.wikipedia.org/wiki/Pemivibart

    Pemivibart, sold under the brand name Pemgarda, is a monoclonal antibody medication authorized for the pre-exposure prophylaxis (prevention) of COVID‑19. [4] Pemivibart was developed by Invivyd. [3] [5] The US Food and Drug Administration (FDA) issued an emergency use authorization for pemivibart in March 2024. [4] [5]

  5. Monoclonal antibody infusions? They're keeping many COVID-19 ...

    www.aol.com/news/monoclonal-antibody-infusions...

    For premium support please call: 800-290-4726 more ways to reach us

  6. COVID Monoclonal Antibody Therapy: Everything You Need ... - AOL

    www.aol.com/news/covid-monoclonal-antibody...

    Millions of Americans are eligible to get the treatment, but not enough know they qualify — and not all three options appear to work on omicron cases. COVID Monoclonal Antibody Therapy ...

  7. Why states are revving up use of monoclonal antibodies as ...

    www.aol.com/news/antibody-treatments-slow...

    For premium support please call: 800-290-4726 more ways to reach us

  8. Bebtelovimab - Wikipedia

    en.wikipedia.org/wiki/Bebtelovimab

    Bebtelovimab was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in February 2022, [2] and revoked it in November 2022. [7] The EUA for bebtelovimab is for the treatment of mild to moderate COVID-19 in people aged 12 years of age and older weighing at least 40 kilograms (88 lb) with a positive COVID-19 test, and who are at high risk for progression to ...

  9. Treatment and management of COVID-19 - Wikipedia

    en.wikipedia.org/wiki/Treatment_and_management...

    On 16 April 2021, the FDA revoked the emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. [69]